



Development and Validation of Chemometric Assisted Methods and Stability Indicating RP-HPLC Method for Simultaneous Estimation of Rasagiline Mesylate and Pramipexole in Synthetic Mixture

Riddhi Patel and Rajashree Mashru*

Faculty of Pharmacy, GH Patel Building, Donor's Plaza, The Maharaja Sayajirao University of Baroda, Vadodara, India

*Corresponding Author: Rajashree Mashru, Faculty of Pharmacy, GH Patel Building, Donor's Plaza, The Maharaja Sayajirao University of Baroda, Vadodara, India.

Received: June 17, 2019; Published: July 31, 2019

DOI: 10.31080/ASPS.2019.03.0359

Abstract

Rasagiline Mesylate is irreversible monoamine oxidase inhibitor used for treatment of Idiopathic Parkinson's disease. Pramipexole is a non-ergotamine dopamine agonist and used for treatment of early stage Parkinson's disease. In combination of both drugs shows synergistic effect. The Chemometric assisted UV method and Stability indicating RP-HPLC method has been developed for the simultaneous estimation of Rasagiline Mesylate and Pramipexole in synthetic mixture. The mobile phase consisted of 10 mM Acetate Buffer: Acetonitrile (75:25 v/v) at 0.8 ml/min flow rate with UV detection at 265 nm. Method found to be linear for both drugs at an analytical range of 15- 90 µg/ml and 6- 36 µg/ml for Rasagiline Mesylate and Pramipexole respectively. Retention time for Rasagiline Mesylate and Pramipexole was 3.3 min and 6.1 min respectively. Force degradation studies were performed by exposition of drug to hydrolytic (acidic and basic), Photolytic and heat stress condition.

Keywords: Rasagiline Mesylate; Pramipexole; Stability Indicating; Chemometric; RP-HPLC

Introduction

Chemometric methods are one type of multivariate analysis i.e. considering more than one variable at a time. When applied to UV spectrophotometry, many wavelengths are taken as variable and absorbance at each wavelength is considered. Least square approach involves mathematical modelling by which the square of residual (difference between actual and predicted concentration) is minimized to lowest level. Four different Chemometric methods are used which are

1. Classical Least Squares
2. Inverse Least Squares
3. Principal Component Regression
4. Partial Least Squares or Projection to Latent Structures

These methods first calibrate the mathematical model by using absorbance data of calibration standards with known concentration and then predict the concentration of un-known samples

from their absorbance data. If there are m number of calibration standards and l chemical components (drugs) and n is the number of wavelengths considered, all methods involve presentation of absorbance data as a matrix with m rows and n columns, concentration data as a matrix with m row and l columns.

According to ICH guidelines stability means "An ability of pharmaceutical product to retain its physical, chemical, microbiological properties within specifications throughout its shelf life" Elaborate definitions of stability-indicating methodology are provided in the United States-Food and Drug Administration (US-FDA) stability guideline of 1987 and the draft guideline of 1998.

Stability-indicating methods according to 1987 guideline were defined as the „Quantitative analytical methods that are based on the characteristic structural, chemical or biological properties of each active ingredient of a drug product and that will distinguish each active ingredient from its degradation products so that the

active ingredient content can be accurately measured." This definition in the draft guideline of 1998 reads as: „Validated quantitative analytical methods that can detect the changes with time in the chemical, physical, or microbiological properties of the drug substance and drug product, and that are specific so that the contents of active ingredient, degradation products, and other components of interest can be accurately measured without interference”.

Ideal characteristics of SIA method

- It should be capable of separating major API from any degradation product under defined storage condition.
- It should be sensitive to detect and quantify one or more degradation products or impurities or related substances.

Modes of degradation

Chemical degradation (solvolysis, oxidation, etc) is common. The cause of chemical deterioration include incompatibility, oxidation, reduction, hydrolysis, racemization etc. oxidation is prime cause of product instability. Drugs containing an ester or amide linkage are prone to hydrolysis.

Photolytic degradation can be an important limiting factor in the stability of pharmaceuticals. A drug can be affected chemically by the radiation of particular wavelength only if it absorbs radiation at that wavelength and the energy exceeds a threshold. UV radiation which has a high energy level is the cause of much degradation. Physical degradation can be caused by range of factors (e.g., impact, vibration, and abrasion and temperature fluctuations).

Potential adverse effects of instability in pharmaceutical products

- Loss of Active Pharmaceutical Ingredient (API)
- Increase in concentration of API
- Alteration in bioavailability
- Loss of content uniformity
- Loss of pharmaceutical elegance and patient acceptability
- Formation of toxic degradation products
- Loss of package integrity

Rasagiline Mesylate is chemically known as (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine, it is an Irreversible Monoamine oxidase inhibitor used for the treatment of idiopathic Parkinson's disease. Molecular formula of Rasagiline Mesylate is $C_{12}H_{13}N$ and molecular mass is 171.238 g/mol. It is white amorphous powder. It is soluble in water and methanol, insoluble in ACN.

Pramipexole is chemically known as (S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine, it is a non-ergoline dopamine agonist indicated for treating early stage Parkinson's disease (PD) and restless legs syndrome (RLS). Molecular formula of Pramipexole is $C_{10}H_{17}N_3S$ and molecular mass is 211.324g/mol. It is white amorphous powder. It is soluble in water and methanol, insoluble in ACN.

Why this combination? [1]

- Monoamine oxidase-B inhibitors or dopamine agonists are approved treatments for early PD patients are associated with efficacy or safety limitations.
- Low doses of the dopamine agonists Pramipexole, and the monoamine oxidase-B inhibitor Rasagiline that have complementary mechanisms of action. Preclinical studies demonstrate that the combination provides synergistic effects, which are further enhanced if both agents are given in slow release.
- The synergy between the combination components implies that lower doses maybe used without compromising the therapeutic effect, while maintaining manageable safety profile, due to the decreased drug amounts.
- Phase III clinical trial for this combination implies that it may provide significant therapeutic effects comparable to those published for higher doses of the individual components, with favourable safety profile.

Several UV methods reported for Rasagiline Mesylate. HPLC method reported for estimation of Rasagiline Mesylate in bulk and tablet dosage form [2-5].

Several UV methods reported for estimation of Pramipexole. HPLC method reported for estimation of Pramipexole [6-9]. There is no single method is reported for simultaneous estimation of Rasagiline Mesylate and Pramipexole in synthetic Mixture.

Materials and Methods

Instrument

Shimadzu UV-1700 double beam spectrophotometer connected to a computer loaded with Shimadzu UV Probe 2.10 software was used for all the spectrophotometric measurements. The absorbance spectra of the reference and test solutions were carried out in 1cm quartz cells over the range of 200-400 nm. The samples were weighed on electronic analytical balance (A×120, Shimadzu). Statistical Analysis of Data was accomplished using Microsoft Excel 2013.

Material and Reagents

Rasagiline mesylate and Pramipexole API

Selection of a solvent

Both the Drugs were soluble in Methanol. So, Methanol was selected as a solvent for estimation of both the Drugs.

Preparation of standard stock and working standard solution

Preparation of standard stock solution of Rasagiline mesylate (1000 µg/ml): Weighed accurately 10 mg of Rasagiline mesylate and was transferred into 10 ml volumetric flask, volume was made up to the mark with Methanol.

Preparation of working standard solution of Rasagiline mesylate (100 µg/ml): Aliquot of 1 ml was withdrawn from the stock solution and transferred into 10 ml volumetric flask and diluted with Methanol to obtain 100 µg/ml.

Preparation of standard stock solution of Pramipexole (1000 µg/ml): Weighed accurately 10 mg of Pramipexole and was transferred into 10 ml volumetric flask, diluted to half and sonicated and made up to the mark with Methanol. (1000µg/ml) Preparation of working standard solution of Pramipexole (100 µg/ml): Aliquot of 1 ml was withdrawn from the stock solution and transferred into 10 ml volumetric flask and diluted with Methanol to obtain 100µg/ml.

Method development [10]

Classical first derivative zero crossing method

Derivative spectra can be used to enhance differences among spectra, to resolve overlapping bands in qualitative analysis and most importantly, to reduce the effects of interference from scattering, matrix or other absorbing compounds in quantitative analysis.

Procedure for selection of wavelength

1.5 ml working standard solution of Rasagiline mesylate (100 µg/ml) and 0.6 ml working standard solution of Pramipexole (100 µg/ml) was transferred into different 10 ml volumetric flask and dilute up to mark with Methanol to get 15 µg/ml of Rasagiline mesylate and 6 µg/ml of Pramipexole. Each solution was scanned in the range of 200-400 nm. Zero Order spectra were converted into First Order spectra. Rasagiline mesylate shows ZCP (Zero Crossing Point) at 286 nm and Pramipexole show ZCP at 228 nm. Hence, these wavelengths 228 and 286 were selected as analytical wavelengths for Rasagiline mesylate and Pramipexole respectively. 1st derivative spectra of Rasagiline Mesylate is shown in Figure 1, Pramipexole in Figure 2 and overlay spectra of both drugs shown in Figure 3.




Figure 1: 1st derivative spectra of Rasagiline mesylate.




Figure 2: 1st derivative spectra of Pramipexole.




Figure 3: Overlain Spectra of RASA and PRAMI.




Figure 4: Overlain spectra of Rasagiline Mesylate and Pramipexole.

Method validation [11]

Developed spectrophotometric methods for the simultaneous estimation of RASA and PRAMI were validated according to ICH Q2 (R1) guidelines and data complying with the standards were obtained. The proposed technique has been extensively validated in terms of linearity, accuracy and precision, limit of detection and limit of quantification.

Linearity and Sensitivity

The linearity of method was evaluated thrice by analyzing six concentration of each drug. Linear regression equation was obtained over the concentration range ($y = mx+c$). Limit of Detection (LOD) and Limit of Quantification (LOQ) were calculated from standard deviation of response and slope of calibration curve. Table reveal the Summary of Validation parameters of RASA and PRAM (Table 3).

Precision

Intraday and Interday precision was measured in terms of % RSD. The experiment was repeated 3 times a day for intraday and for 3 different days for inter-day precision. The average % RSD was found to be less than 2.0% for both the methods (Table 4).

Accuracy

To check the Accuracy of different methods, Recovery studies were carried out from pre-analyzed sample at three different level of standard addition 80%, 100% and 120%. Results of Recovery studies are shown in Table 5. For each of the method explained above, %Recovery was the average of three determinations at each standard addition level. %Recovery for different methods was found to be between 98%-102% which prove that all the methods were accurate (Table 5).




Figure 5: Calibration curve for - First derivative ZCP method.

Applicability of Proposed Uv Method

Result of Simultaneous estimation of RASA and PRAMI in synthetic mixture given in Table 6.

Chemometric Methods [12-15]

Chemometric methods are one kind of multivariate analysis in which multiple measurements are made on a sample of interest. So, more than one variable or response are measured for each sample.

The Chemometric quantitative analytical techniques have many applications and advantages such as

- Allow the resolution of the complex spectra of mixtures of analytes.
- The mixtures can be analyzed without any separation procedures for drug determination.
- The techniques are very easy to apply, very sensitive, useful and yet very inexpensive as compared to other analytical techniques for simultaneous determination of compounds in multicomponent mixtures.
- Allow the interpretation of multivariate data and is vital to the success of the simultaneous determination of the organic components.

Multivariate methods include two type of methods

- Factor-based methods:
- Principal Component Regression (PCR)
- Partial Least Squares (PLS)

Preparation of binary mixtures (RASA + PRAMI) for calibration set and validation set

- Appropriate and accurate volume aliquots of the stock solutions were taken according to following Binary mixture scheme and volume made up to 10 ml with methanol.

- The absorbance data matrix was obtained by measuring the absorbance at each wavelength points (250 to 275 nm) in spectral region between 250 to 275 nm.
- 36 sets are taken for Calibration set and for validation set.

Calibration Set

A set of 26 mixtures was prepared in methanol, applying a multilevel multifactor design in which two levels of concentrations of RASA and PRAMI within the stated range were introduced as shown in Table 1.

RASA (ppm)	PRAMI (ppm)
75	30
15	30
90	18
45	18
90	30
90	12
90	36
30	18
60	12
75	6
30	12
15	24
45	30
30	30
60	30
15	12
15	6
75	24
90	24
45	36
60	36
45	6
30	24
60	24
60	18
75	36

Table 1: Calibration Set.

Validation set

A set of 10 mixtures was prepared in water, applying a multilevel multifactor design in which two levels of concentrations of RASA and PRAMI within the stated range were introduced as shown in Table 2.

RASA	PRAMI
90	6
75	12
30	36
15	36
45	12
30	6
75	18
45	24
15	18
60	6

Table 2: Validation Set.

Producing absorbance matrix A

Absorbance matrix A was produced by measuring absorbance at 26 wavelengths in the spectrum region between the 250 nm to 275 nm. This region was selected because it contained most relevant information about both the drugs. The spectra of prepared binary mixture standards were recorded in the range of 250 to 275 nm. Absorbance values in this wavelength region were recorded figure 6.




Figure 6: Overlain spectra of PRAMI and RASA and mixture.

Principal component regression

PCR is the method which works on the principal of reducing the dimensionality of the original data. Absorbance matrix and concentration matrix as shown above were generated and data was fed to software. The absorbance matrix (X) used for calibration contains total 26 variables i.e. wavelengths at which absorbance values are measured. PCR will compute a few PCs and will perform regression of these PCs with concentration (Y). Validation was set as full cross validation. The data of absorbance values at 26 wavelengths were used as X space (predictors) and the data containing concentration of RASA and PRAMI in 26 calibration standards were used as Y space (responses) (Figure 7 and 8).




Figure 7: Total explained Y variance.




Figure 8: Total residual Y variance.

Determining optimum number of principal components for PCR

Three major parameters are considered for determination of number of PCs to be taken into account.

Effect of number of PCs on Explained Y-variance (PCR) – should be high (Near To 100) Effect of number of PCs on Residual variance (PCR) – should be low (Near to Zero).

Determining optimum number of principal components for PCR

Three major parameters are considered for determination of number of PCs to be taken into account.

Effect of number of PCs on Explained Y-variance (PCR) – should be high (Near To 100) Effect of number of PCs on Residual variance (PCR) – should be low (Near to Zero).

Root mean square of prediction values for validation

(Concentrations are Y space – the responses; and absorbance values at different wavelengths are considered as X space – the predictors. Mixtures prepared as calibration standards may be referred to as samples.)

The model should have as low residual variance as possible. This means that the model should explain most of the variance in the data i.e. explained variance should approach 100%. For this, number of PCs should be optimized. Normally, first 2-3 PCs will explain nearly (not exactly) 100% of variance in data. Moreover, the model should have as low RMSEP values as possible.

- The software can validate the model by full cross validation method, where one sample from the calibration set is left out each time and model is calibrated using remaining samples. Then the prediction is made for left out sample and its residual is calculated. The same process is repeated until each sample is left out once. So, there were total 17 segments for validation, because there were 17 calibration standards or samples. Finally, one can view the plot of residual variance or explained variance (for calibration and validation both) or RMSEP vs. number of PCs. This can help in determining the optimum number of PCs.
- Once the model is calibrated with optimum number of PCs, the model can predict the unknown concentration from its absorbance data.
- Maximum number of PCs was fixed to 7 and the parameters are discussed below.

Partial least squares or projection to latent structures

Theoretical Aspects of this method are explained in Chapter1, Section 1.5. PLS computes factors for X and Y both and then correlates them. It models both the X- and Y-matrices simultaneously to find the latent variables in X that will best predict the latent variables in Y. Full cross validation method is used for determining the optimum number of factors (Figure 9 and 10).




Figure 9: Total explained Y variance.




Figure 10: Total residual Y variance.

The algorithm used for PLS was NIPALS i.e. nonlinear iterative partial least squares.

Determining Optimum Number of Principal Factors for PLS

The number of factors to be taken into account was determined by full cross validation method and following parameters were considered:

1. Total explained Y variance
2. Total residual Y variance
3. RMSEP values for validation

Validation of PCR and PLS models

The validation set prepared as described in previous was subjected to analysis by developed models of all the four methods. Though the PCR and PLS models are validated using full cross validation, these methods are also applied to validation set. The validation parameters are discussed below.

Predicted vs. actual concentration plot

Predicted vs. Actual concentration plots for RASA and PRAMI for all four different methods are shown below in Figure 11 and Figure 12 respectively. Predicted concentration of validation samples were plotted against the actual concentration values. This tool is used to determine whether the model accounts for concentration variation in the validation set or not. Plots were expected to fall on straight line with slope of 1 and 0 intercept. It was noticed RASA and PRAMI in all samples lay on straight line and the equations of these lines are shown on the graph. This indicates that the prediction ability of the validation set is very much better in terms of recovery (figure 11-14).




Figure 11: Predicted vs Actual Conc of RASA.




Figure 12: Predicted vs Actual Conc of PRAMI.




Figure 13: Predicted vs Actual Conc of RASA for PLS.




Figure 16: Residual vs Actual Conc of PRAMI for PCR.




Figure 14: Predicted vs Actual Conc of PRAMI for PLS.




Figure 17: Residual vs Actual Conc of RASA for PLS.

Residual vs. Actual concentration plot the differences between the actual and predicted concentration (Residuals) were plotted against actual concentration of validation samples. This tool is used to determine whether the model accounts for the concentration variation in the validation set and it also provides information about how well the method will predict the future sample. For the validation set it can be found that the residual values more close to zero and more randomly distributed (Figure 15-18).




Figure 15: Residual vs Actual Conc of RASA for PCR.




Figure 18: Residual vs Actual Conc of PRAMI for PLS.

RMSEP value

Root Mean Square Error of Prediction (RMSEP)

The predictive ability of the model can be defined as RMSEP. RMSEP summarizes both Precision and Accuracy. It is used for examining the errors in the predicted concentration. It is calculated from following formula.

$$RMSEP = \sqrt{\frac{\sum_{i=1}^n (\hat{y}_i - y_i)^2}{n}}$$

Where, N is the number of samples used for validation i.e. 8. The results of future predictions can then be presented as “predicted values $\pm 2 \cdot \text{RMSEP}$ ” (Table 7).

Applicability of The Developed Chemometric Methods

All four methods were successfully applied for the estimation of PRAMI and RASA in synthetic mixture (Table 8).

Development and Validation for Simultaneous Estimation of Rasagiline Mesylate and Pramipexole in Bulk and Synthetic Mixture by Isocratic Reverse Phase - High Performance Liquid Chromatographic (Rp-Hplc) Method.

HPLC instrumentation

Chromatography was performed on Shimadzu (Shimadzu Corporation, Kyoto, Japan) chromatographic system equipped with Shimadzu LC-20AT pump and Shimadzu SPD-20AV absorbance detector. Samples were injected through a Rheodyne 7725 injector valve with fixed loop at 20 μL . Data acquisition and integration was performed using LC Solutions software. HyperChrom ODS-BP (250 mm x 4.6 mm, 5 μm) was used for separation.

Reagents and chemicals

Rasagiline Mesylate and Pramipexole API.

Acetonitrile (HPLC grade, Spectrochem Pvt Ltd, Mumbai). Double distilled water (Purified HPLC grade water was obtained by filtering double distilled water through nylon filter paper 0.2 μm pore size and 47 mm diameter. Ammonium acetate buffer HPLC grade.

Preparation of standard stock and working standard solutions

- **Preparation of standard stock solution of Rasagiline Mesylate (1000 $\mu\text{g/ml}$):** Weighed accurately 10 -mg of Rasagiline Mesylate and was transferred into 10 ml volumetric flask, volume was made up to the mark with Methanol. (1000 $\mu\text{g/ml}$)
- **Preparation of working standard solution of Rasagiline Mesylate (100 $\mu\text{g/ml}$):** Aliquot of 5 ml was withdrawn from the stock solution and transferred into 50 ml volumetric flask and diluted with Methanol to obtain 100 $\mu\text{g/ml}$.
- **Serial dilutions of Rasagiline Mesylate (15 - 90 $\mu\text{g/ml}$):** Withdraw 1.5, 3, 4.5, 6, 7.5, and 9.0 ml from the working standard solution and each transferred into 10 ml volumetric flasks and diluted with Methanol to obtain 15, 30, 45, 60, 75, 90 $\mu\text{g/ml}$ respectively.

- **Preparation of standard stock solution of Pramipexole (1000 $\mu\text{g/ml}$):** Accurately weighed 10mg of Pramipexole and was transferred into 10 ml volumetric flask, diluted to half and sonicated and made up to the mark with Methanol. (1000 $\mu\text{g/ml}$)
- **Preparation of working standard solution of Pramipexole (100 $\mu\text{g/ml}$):** Aliquot of 25 ml was withdrawn from the stock solution and transferred into 25 ml volumetric flask and diluted with Methanol to obtain 100 $\mu\text{g/ml}$.
- **Serial dilutions of Pramipexole (6, 12, 18, 24, 30, 36 $\mu\text{g/ml}$):** Withdraw 0.6, 1.2, 1.8, 2.4, 3.0 and 3.6 ml from the working standard solution and each transferred into 10 ml volumetric flasks and diluted with Methanol to obtain 6, 12, 18, 24, 30 and 36 $\mu\text{g/ml}$ respectively.

Method development

Selection of analytical wavelength

Standard solutions of RASA and PRAMI were scanned between 200-400 nm in UV-visible spectrophotometer and showed good sensitivity at 265 nm as shown in Figure 19 which was selected as the analytical wavelength.




Figure 19: Overlain spectra of PRAMI and RASA.

Method validation

Developed RP-HPLC method was validated according to ICH Q2 (R1) guidelines and data complying with the standards were obtained.

Linearity

The calibration curve was constructed by plotting concentrations of RASA and PRAMI versus their respective peak areas, and the regression equations were calculated. The linearity of the method was investigated by using concentrations in the range 15-

90 µg/ml for RASA and 6- 36 µg/ml for PRAMI. Retention times for RASA and PRAMI were found to be 3.325 min and 6.148 min respectively. Overlay spectra of combination shown in Figure 20.




Figure 20: Calibration curve overlay.

Recovery studies

Accuracy of the method was studied using standard addition method at three different levels (80, 100, and 120%) by recovery experiments. Known amounts of standard solutions containing RASA and PRAMI were added to prequantified sample solutions to reach 80%, 100% and 120% levels. Percentage Recovery was the mean of three determinations at each standard addition level (Table 9).

Precision

To demonstrate agreement among results, a series of measurements were done. Three replicate injections of specific standard at various time intervals on the same day were injected into system for intraday precision and were repeated on three different days for interday precision. The % RSD (Relative Standard Deviation) of the results was calculated (Table 10).

Sensitivity

The limit of detection (LOD) and limit of quantification (LOQ) which determines the sensitivity of method are calculated by equation 1 and 2

$$\text{LOD} = 3.3 \sigma/S \dots\dots\dots (1)$$

$$\text{LOQ} = 10 \sigma/S \dots\dots\dots (2)$$

Where “ σ ” is the standard deviation of intercepts and “S” is the slope of response (Table 11).

System suitability parameters

System suitability testing was carried out on freshly prepared standard solution (n = 6) of RASA and PRAMI. System suitability

parameters obtained with 20µl injection volumes are summarized in Table 12.

Summary of validation result for developed method is given in Table 13.

Applicability of proposed method

Assay

Tablets were crushed to powder and were dissolved in 10ml of methanol. Solution was centrifuged and filtered through 0.2µm syringe filter. 1ml aliquot was drawn and volume was made up to 10ml with mobile phase and sample was injected into HPLC (Table 14).

Forced degradation study

Stress conditions under which a drug is forced degraded are fairly constant, the time of exposure and extent of degradation may vary from day to day. The general guideline for developing a stability-indicating assay procedure is to expose the drug to stress conditions to produce sufficient degradation. The stability-indicating assay method should be able to estimate the remaining drug without the interference of known or unknown degraded product.

For development of stability-indicating assay method, stress degradation is important. By degrading the drug under stress condition, we can understand the path of degradation, degradation kinetics, which products are going to be formed due to degradation.

To ascertain a method’s stability-indicating capability, it is necessary to perform a forced degradation study. Generally, a forced degradation study is performed prior to commercial stability testing by exposing the drug to variety of extreme condition, such as pH, photolysis, oxidation and temperature; over a very short time period.

Drug is exposed to a range of pH levels to ascertain the drug’s susceptibility to hydrolysis. Photolysis of drug demonstrates whether exposure to light result in unacceptable changes. Oxidation and elevated temperatures potentially generate a variety of impurities that may differ from that of the photolysis or pH condition. The degraded drug products provide information in to the potential impurities of the drug that may be generated during stability testing. Forced degradation studies can also be used to quickly assess packaging material compatibility or sensitivity

Forced degradation studies of bulk drug and synthetic formulations

In order to determine whether the developed analytical method was stability indicating, active pharmaceutical ingredient (API) and synthetic formulation of PRAMI and RASA were degraded under various stressed conditions to conduct forced degradation studies.

For API and synthetic formulations, stock solution of PRAMI and RASA (1:2.5) was prepared separately in Methanol (Preparation of std stock solution) These stock solutions were used for forced degradation studies to provide an indication of the stability indicating property and specificity of proposed method.

Preparation of acid induced degradation product

Accurately weighed 24mg and 60mg of PRAMI AND RASA respectively, were taken in 10mL volumetric flask separately and dissolved in 4mL of Methanol The volume was made up with 0.1N HCL and was kept at RT. Then 1mL of above solution was withdrawn and was neutralized with 0.1N NaOH. Then sample was diluted upto mark with diluent i.e. mobile phase and subjected to analysis.

Preparation of base induced degradation product

Accurately weighed 24mg and 60mg of PRAMI AND RASA respectively, were taken in 10mL volumetric flask separately and dissolved in 4mL of Methanol The volume was made up with 0.1N NaOH and was kept at RT. Then 1mL of above solution was withdrawn and was neutralized with 0.1N HCL. Then sample was diluted upto mark with diluent i.e. mobile phase and subjected to analysis (Figure 21,22).

Photochemical degradation

For the photochemical stability, the mixture of solid drugs (API) was spread in 1mm thickness on a petridish and exposed to 5382 LUX and 144UW/cm² for 1 days. Degradation samples were subjected to analysis after suitable dilutions with Mobile phase (Figure 23).

Dry heat induced degradation

For preparing dry heat degradation product, API of PRAMI and RASA were placed in oven at 70°C for 1 days under dry heat condition in the dark and then cooled to room temperature. Degradation samples were subjected to analysis after suitable dilutions with Mobile phase (Figure 24,25).

Preparation of degradation sample of prepared laboratory mixture

The specifications for preparation of the laboratory synthetic mixture are mentioned in last section. 1mL of prepared synthet-

ic mixture was withdrawn accurately and transferred to a 10 mL volumetric flask containing suitable stressor. Aliquot of 1 mL was withdrawn accurately and neutralized if required, finally the volume being made upto 10 mL using Mobile phase. For Photochemical, Dry heat and Thermal-Humidity induced degradation, suitable amount of laboratory mixture was spread uniformly and subjected to stressor treatment as specified. Appropriate dilutions of the degradation samples were then subject to analysis (Table 15).

Preliminary studies

First of all, stressor concentration, stressor temperature and stressor time was optimized individually for both drugs to achieve an appropriate degradation. Then these conditions were optimized for both drugs together. Finally optimized stressor condition for both drugs together:




Figure 21: Control chromatogram. (PRAMI and RASA at RT mp and analysed. Results of Forced degradation studies.

Results of Forced degradation studies

Acid- induced degradation




Figure 22: Acid degradation of mixture PRAMI and RASA (2hr)

Base induced degradation




Figure 23: Base degradation of mixture PRAMI and RASA (2hr).

Dry Heat Induced Degradation




Figure 24: Dry heat studies at 70°C of PRAMI and RASA after 1 days. (intensity of the peaks remain consistent with all the time intervals).

Photochemical degradation




Figure 25: Dry heat studies at 70°C of PRAMI and RASA after 1 days. (intensity of the peaks remain consistent with all the time intervals).

Result and Discussion

Analytical Parameter	First Derivative ZCP	
	RASA	PRAMI
Drugs	RASA	PRAMI
$\lambda_{max, nm}$	272 nm	262 nm
LINEARITY	15-90 $\mu\text{g/ml}$	6-36 $\mu\text{g/ml}$
Slope	-0.0003	-0.0010
Intercept	0.0025	0.0016
Correlation coefficient	0.994	0.995
Standard Deviation of Intercept	0.00036	0.00033
LOD	3.976	1.117
LOQ	12.05	3.385

Table 3: Linearity study.

Parameters	First Dvt. ZCP	
	RASA	PRAMI
Intraday %RSD	0.293	0.214
Interday RSD	0.296	0.219

Table 4: Precision Studies.

Drug	First Derivative ZCP method		
	%spiking	Base Conc.	%recovery SD
RASA	80	50 $\mu\text{g/ml}$	99.44% \pm 0.18
	100		100.47 \pm 0.26
	120		101.9 \pm 0.19
PRAMI	80	20 $\mu\text{g/ml}$	101.28 \pm 0.75
	100		101.22 \pm 0.76
	120		99.93 \pm 0.18

Table 5: Recovery Studies.

Applicability of proposed UV method

Result of Simultaneous estimation of RASA and PRAMI in synthetic mixture.

Sr. No	Method	Synthetic Mixture Label Claim: RASA: PRAMI 0.75:0.3 mg	
		% Assay	
1	ZCP	RASA \pm SD	PRAMI \pm SD
		101.44 \pm 0.36	99.25 \pm 0.33

Table 6: Assay of proposed UV Method.

Drug	RMSEP	
	PCR	PLS
RASA	0.00954	0.00954
PRAMI	0.00964	0.00954

Table 7: RMSEP value.

Applicability of the developed chemometric methods

All four methods were successfully applied for the estimation of PRAMI and RASA in synthetic mixture.

Method	RASA	PRAMI
PCR	99.764 ± 0.298	102.614 ± 0.773
PLS	100.16 ± 0.149	101.503 ± 0.572

Table 8: Applicability of Methods.

% spiking	Concentration actual (µg/ml)		Concentration added (µg/ml)		Concentration added (µg/ml)		%Recovery ± SD; n=3	
	RASA	PRAMI	RASA	PRAMI	RASA	PRAMI	RASA	PRAMI
80	100	40	80	32	80.5	31.6	100.65 ± 0.842	98.84 ± 0.953
100			100	40	100.5	39.8	101.58 ± 1.262	99.73 ± 0.639
120			120	48	119.8	47.6	99.85 ± 1.30	99.33 ± 0.507

Table 9: Accuracy results of RASA and PRAMI (HPLC).

CONC. (µg/ml)		Intraday precision				Interday precision			
		MEAN AREA ± SD; n=3		%RSD		MEAN AREA ± SD; n=3		%RSD	
RASA	PRA-MI	RASA	PRAMI	RASA	PRA-MI	RASA	PRAMI	RASA	PRA-MI
40	20	5891 03 ± 7409.1	96427.3 ± 982.8 57	0.693	1.737	592735 ± 4348.5 8	96585. 7 ± 934.18 3	0.733	1.096
100	40	7639 95 ± 7814. 56	1188 37 ± 1125. 39	0.804	0.947	756101 ± 6174.4 1	116390 ± 1233.5 4	0.816	1.059
150	60	923118 ± 10782.8	1344 13 ± 1554.18	1.168	1.152	9166487 ± 6315.5 1	134346 ± 1369.9 3	0.689	1.017

Table 10: Precision results in HPLC.

PARAMETER	RASA	PRAMI
LOD(µg/ml)	0.0583	0.1768
LOQ(µg/ml)	0.1036	0.3141

Table 11: LOD and LOQ HPLC.

Parameter	Data obtained	
	RASA	PRAMI
RETENTION TIME ± SD	6.124 ± 0.073	3.325 ± 0.053
Theoretical plate ± SD	2339 ± 132.672	4898 ± 141.623
Tailing factor ± SD	1.968 ± 0.020	1.2 ± 0.031
Resolution ± SD	6.538 ± 0.259	12.695 ± 0.147

Table 12: System Suitability results.

Summary of validation results for the developed method

Parameter	RASA	PRAMI
Analytical Wavelength (Nm)	265 nm	
Retention Time (Min)	6.1 min	3.3 min
Linearity (Mg/ml)	15-90 µg/ml	6- 36µg/ml
Regression Equation	y = 608x + 76340	y = 8910x + 37081
Interday Precision (%Rsd)	1.057	0.746
Intraday Precision (%Rsd)	1.278	0.888
LOD	0.176	0.058
LOQ	0.314	0.103
Accuracy (%Recovery)	102.32	98.612

Table 13: Summary of Validation parameters.

Sample	Label claim	Avg Amount found	%Assay (Avg±SD); n=6	%RSD
RASA	0.75 mg (10 mg)	9.970 mg	99.70 ± 412	0.422
PRAMI	0.3 mg (4 mg)	3.95mg	98.751 ± 0.364	0.377

Table 14: Assay results HPLC.

Stressor condition	Stressor concentration	Stressor temperature	Stressor time
Acidic	0.1N HCl	RT	2 hrs
Basic	0.1N NaOH	RT	2 hrs
Photostability	5382 LUX and 144UW/cm ²	--	1days
Dry heat stability	-	70°C	1days

Table 15: Degradation Study Parameters.

Summary of Forced Degradation Studies

Stressor Type	Stressor Concentration	Stressor Time	% Degradation (Api)		% Degradation (Synthetic Formulation)	
			RASA	PRAMI	RASA	PRAMI
ACIDIC	0.1N HCL at RT	2hrs	39.5%	23.7%	40.2%	23.3%
BASIC	0.1N NaOH at RT	2hrs	41.34%	3.8%	41.2%	3.4%

Table 16: Summary Of Forced Degradation Studies.

Conclusion

Application of Chemometric to UV Spectrophotometry is an effective tool for simultaneous estimation of Rasagiline Mesylate and Pramipexole which offers striking advantage in terms of time required for analysis, simplicity, accuracy and precision. Developed RP-HPLC method found to be stability indicating all the models are found to be applicable for analysis of synthetic mixture. The methods were validated and satisfactory results were produced. PCR and PLS methods were also validated using full cross validation model.

Bibliography

- Warren Olanow MD., et al. "A Randomized Trial of a Low- Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson's Disease C". *Movement Disorders* 32.5 (2017): 783-789.
- Patel Pinal R. "Development and Validation of a Spectrophotometric method for estimation of Rasagiline Mesylate in bulk and tablet dosage Form". *International Journal of Drug Development and Research* (2013).
- Rama Bukka and Kalyani Prakasam. "Uv Spectrophotometric Method For The Determination Of Rasagiline Mesylate In Bulk And Pharmaceutical Formulations". *International Journal of Pharmaceutical Sciences Review and Research* 5.1 (2010): 5-7.
- Vijaya Lakshmi1 JVLN., et al. "Development and Validation Of Rp-Hplc Method For The Estimation Of Rasagiline Tablet Dosage Forms". *Journal of Chemistry* 3.4 (2010): 621-624.
- PG Shelke and AV Chandewar P. "Validated high performance liquid chromatographic method for determination of Rasagiline Mesylate under oxidative, photolytic and thermal stress Conditions". *IndiaInternational Journal of PharmTech Research* 6.2 (2014).
- Ramadevi Uppara R., et al. "Analytical Method Development and Validation of Pramipexole In Bulk and Formulations By Using Uv Spectroscopic Technique". *European Journal of Pharmaceutical and Medical Research* (2017).
- By P Lavudu., et al. "Rp-Hplc Method for the Determination of Pramipexole Dihydrochloride in Tablet Dosage Form". *Global Journal of Medical research* 12.4 (2012).

8. vilas Chaudhary¹ and Milind Ubale. "Development and Validation Of Rp-Hplc Method For Estimation Of Pramipexole Hydrochloride In Pharmaceutical Dosage Form". *International Journal of Research In Pharmacy And Chemistry* 3.1 (2013).
9. Shubhangi M., *et al.* "Establishment of inherent stability of pramipexole and development of validated stability indicating LC-UV and LC-MS method". *Journal of Pharmaceutical Analysis* 3.2 (2013):109-117.
10. Beckett AH and Stenlake JB. "UV-visible Spectrophotometry". *Practical Pharmaceutical Chemistry*, 4th ed., Part-II, C.B.S. Publishers, Delhi (2001): 285-297.
11. ICH Q2 (R1). "Validation of analytical procedure Text and methodology". Geneva, International conference on Harmonization (2005).
12. Prachi Bhamre., *et al.* "Simultaneous determination of Doxylamine succinate, Pyridoxine hydrochloride and folic acid by Chemometric spectrophotometry". *International Journal of Pharma and Bio Sciences* 4.1 (2013): 738 – 749.
13. Garcia H and Filzmoser P. "Multivariate Statistical Analysis using the R package Chemometrics". (2011).
14. James N Miller and Jane C Miller. "Statistics and Chemometrics for Analytical Chemistry". 5th edition, Pearson Education Limited Edinburgh Gate, Harlow Essex (2005).
15. Richard Kramer. "Applied Chemometrics Inc. Chemometric technique for quantitative analysis, Marcel Dekker Inc. New York (1998).

Volume 3 Issue 8 August 2019

© All rights are reserved by Riddhi Patel and Rajashree Mashru.